In another research conducted by Fujiwara et al., in 2015, when assessed serum biomarker levels of CA-125 and HE-4 in 225 Japanese women with ovarian cancer and 94 healthy controls, a sensitivity of 92.1% in type-I and 78.8% for type-II were recorded when tested together. This evidence concerns the gene MUC16 and ovarian carcinoma.